Solid performance and promising outlook for Galenica in 2024

In 2024, Galenica AG posted solid growth with a 4.7% increase in sales to CHF 3,921.1 million. Adjusted EBIT increased by 10.3% to CHF 211 million. Adjusted net profit increased by 13.4% to CHF 183.2 million. This performance exceeded expectations and strengthened its market position.

For 2025, Galenica expects sales growth of between 3% and 5%, with adjusted EBIT increasing by 4% to 6%. The company continues to invest in its infrastructure and improve its digital services, including the introduction of a digital prescription manager and the expansion of the Lifestage Solutions platform for the home care sector.

The pharmacy network also strengthened its presence in Switzerland with ten new pharmacies, thereby increasing accessibility to care. In addition, demand for health consulting services increased significantly, highlighting the strategic importance of pharmacies in providing local care.